Dashboard
Manage Tickers

RARE Ultragenyx Pharmaceutical Inc.

Nasdaq ultragenyx.com


$ 32.91 $ -1.13 (-3.27 %)    

Monday, 03-Nov-2025 16:08:33 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.77 $ 0.00 (0 %)
DIA $ 470.08 $ 0.00 (0 %)
SPY $ 676.51 $ 0.00 (0 %)
TLT $ 89.86 $ 0.00 (0 %)
GLD $ 367.33 $ 0.00 (0 %)
$ 33.47
$ 34.00
$ 32.00 x 2
$ 35.50 x 300
-- - --
$ 25.81 - $ 53.47
1,407,583
na
3.23B
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-15-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-K
20 10-27-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-20-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-21-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

ultragenyx-doses-first-patient-in-aurora-study-evaluating-gtx-102-in-additional-angelman-syndrome-genotypes-and-age-groups
Ultragenyx Doses First Patient In Aurora S...
10/30/2025 12:05:20

ionis-pharmaceuticals-to-expedite-development-of-rare-neurological-disease-candidate-with-fda-breakthrough-status
Ionis Pharmaceuticals To Expedite Developm...
09/09/2025 17:51:26

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

hc-wainwright--co-reiterates-buy-on-ultragenyx-pharmaceutical-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Ultr...
09/09/2025 10:16:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintai...

ultragenyx-reports-96-week-phase-3-results-for-dtx401-in-gsdia-showing-greater-reductions-in-cornstarch-use-and-sustained-glycemic-control
Ultragenyx Reports 96-Week Phase 3 Results...
09/08/2025 20:18:59

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglyc...

assessing-ultragenyx-pharmaceutical-insights-from-8-financial-analysts
Assessing Ultragenyx Pharmaceutical: Insig...
09/05/2025 14:01:03

cantor-fitzgerald-reiterates-overweight-on-ultragenyx-pharmaceutical-maintains-105-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/05/2025 13:44:07

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

fda-outlines-process-to-speed-up-rare-disease-therapy-approvals
FDA Outlines Process To Speed Up Rare Dise...
09/04/2025 18:50:03

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/02/2025 17:35:29

ultragenyx-initiates-rolling-submission-of-a-biologics-license-application-to-the-fda-for-its-dtx401-aav-gene-therapy-in-glycogen-storage-disease-type-ia
Ultragenyx Initiates Rolling Submission Of...
08/18/2025 12:04:53

canaccord-genuity-maintains-buy-on-ultragenyx-pharmaceutical-lowers-price-target-to-128
Canaccord Genuity Maintains Buy on Ultrage...
08/08/2025 21:36:37

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...

8-analysts-assess-ultragenyx-pharmaceutical-what-you-need-to-know
8 Analysts Assess Ultragenyx Pharmaceutica...
08/06/2025 22:01:05

cantor-fitzgerald-maintains-overweight-on-ultragenyx-pharmaceutical-lowers-price-target-to-105
Cantor Fitzgerald Maintains Overweight on ...
08/06/2025 14:17:39

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the ...

ultragenyx-pharmaceutical-affirms-fy2025-sales-guidance-of-64000m-67000m-vs-65327m-est
Ultragenyx Pharmaceutical Affirms FY2025 S...
08/05/2025 20:02:45

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2025 sales outlook from $640.00 million-$670.00 million to $640.00 million-$6...

ultragenyx-pharmaceutical-q2-eps-117-beats-132-estimate-sales-16650m-beat-16250m-estimate
Ultragenyx Pharmaceutical Q2 EPS $(1.17) B...
08/05/2025 20:01:57

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimat...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/04/2025 21:07:07

what-to-expect-from-ultragenyx-pharmaceuticals-earnings
What to Expect from Ultragenyx Pharmaceuti...
08/04/2025 17:04:13

ultragenyx-completes-enrollment-in-its-phase-3-aspire-study-of-apazunersen-for-angelman-syndrome
Ultragenyx Completes Enrollment In Its Pha...
07/31/2025 20:42:33

ultragenyx-represents-intriguing-buying-opportunity-despite-recent-setbacks
Ultragenyx Represents 'Intriguing Buying O...
07/28/2025 17:16:04

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION